Recommended dosing regimen for Quizartinib

Quizartinib, also known as Vanflyta, is a selective FLT3 tyrosine kinase inhibitor specifically targeting acute myeloid leukemia (AML). Its main mechanism of action is by inhibiting the activation of the FLT3 receptor, especially the FLT3-ITD mutant, thereby effectively preventing the abnormal proliferation and survival of leukemia cells. Therefore, the dosage and regimen of quizartinib will be adjusted based on the patient's specific treatment stage (such as induction, consolidation, and maintenance) and individual circumstances (such as electrocardiogram QT interval).

During the induction treatment phase, quizartinib is usually used in combination with cytarabine and anthracyclines, following the "7+3" or "5+2" regimen. During the 28 day induction cycle, from 8 day to 21 day, the patient received 35.4mg of quizartinib once daily. If the patient still has significant clinical symptoms or residual leukemia, a second induction cycle may be required with the same dose and regimen as the first cycle.

When entering the consolidation phase, quizartinib will be combined with high-dose cytarabine. During each 28 day consolidation cycle, patients received 35.4mg of quizartinib once daily from day 6 to day 19 for up to four consolidation cycles.

During maintenance therapy, the dose of quizartinib needs to be adjusted appropriately according to the patient's QT interval. If QTcF is at 450 milliseconds or less, give < on days 1 to 14 of the maintenance cycle span>26.5mg once daily dose; if QTcF remains within safe range, dose may be increased to daily from 15 to 28 days53mg. If QTcFexceeds 500ms, the daily dose of 26.5mg should be maintained. During and after the 2 cycle of the maintenance period, the patient will continue to take medication according to the determined dose of the 1 cycle in each 28 day maintenance cycle, up to 36 cycles.

It should be noted that for patients planning to undergo hematopoietic stem cell transplantation (HSCT), the use of quizartinib must be stopped 7 days before transplantation. In addition, during treatment with quizartinib, patients should undergo regular electrocardiograms and other necessary medical monitoring to ensure the safety and effectiveness of the treatment.

Quizatinib oral tablets are available in two dosage strengths: 17.7mg and 26.5mg, providing patients with greater flexibility. However, specific dosage and administration regimens should be determined by the physician based on the patient's individual condition and response to treatment. During the use of Quizartinib, patients need to strictly follow medical instructions and pay close attention to any potential side effects or adverse reactions.

xa0

References: https://www.pharmacytimes.com/view/clinical-overview-of-quizartinib-for-acute-myeloid-leukemia